FindTrial
Sign In

PMCJ-9 (BCG Connaught strain) phase III clinical study

PMCJ-9 (BCG Connaught strain) phase III clinical study

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220126
Enrollment
Unknown
Registered
2005-09-21
Start date
2005-09-21
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent or multiple NMIBC

Interventions

investigational material(s) Generic name etc : PMCJ-9(BCG Connaught strain) INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Inve

Sponsors

Nippon Kayaku Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Granting of written informed consent by the patient 2. Resection of all tumors by TURBT, tumors are histopathologically confirmed NMIBC ( transitional carcinoma). 3. Sufficient function of the major organs 4. Performance status 0-2 etc.

Exclusion criteria

Exclusion criteria: 1. Muscle-invasive bladder cancer 2. Carcinoma in situ (CIS) or history thereof 3. History of systemic chemotherapy, intra-arterial chemotherapy or radiation therapy for bladder cancer 4. Patient having an immunosuppressive thrapy, etc.

Design outcomes

Primary

MeasureTime frame
Recurrence-free survival time, safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026